Recent years have seen rising concerns over increasing antibiotic resistance of the gonorrhea-causing bacterium, Neisseria gonorrhoeae. This is especially true for third-generation cephalosporins, which are currently recommended for the treatment of such infections. Therefore, susceptibility to these antibiotics should be monitored internationally to the greatest extent possible. The susceptibility of N. gonorrhoeae strains to ceftriaxone and penicillin, as well as production of beta-lactamase by the Cefinase test was determined. Moreover, the presence and type of penicillinase plasmids were determined by PCR. All strains were susceptible to ceftriaxone, the minimal inhibitory concentration (MIC) values ranged from 0.002 to 0.125 mg/L; MIC50 was =0.016 mg/L and MIC90 was =0.064 mg/L. As much as 7.7 % of the strains demonstrated ceftriaxone MIC of 0.125 mg/L. For penicillin, the MICs ranged from 0.064 to 32 mg/L; MIC50 was =0.5 mg/L and MIC90 was =4 mg/L. It was shown that only 1.5 % of the strains were sensitive to penicillin according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Among the penicillin-resistant strains, six (30.0 %) produced penicillinase. The MICs of penicillin were substantially higher for penicillinase-producing than for penicillin-resistant, penicillinase-negative strains. MICs of ceftriaxone for penicillinase-producing strains were low (0.002-0.016 mg/L). Three of the penicillinase-producing strains possessed plasmids of African type (50 %) and three Toronto/Rio type (50 %). An increase of the proportion of beta-lactamase-positive strains in the last years as well as emergence of strains with elevated MIC of ceftriaxone indicate a need to constantly monitor N. gonorrhoeae strains for their susceptibility to beta-lactam antibiotics, as well as for their ability to produce beta-lactamases.

Department of Dermatology and Venereology Medical University of Warsaw Koszykowa 82A 02 008 Warsaw Poland

Department of Medical Microbiology Medical University of Warsaw Chalubinskiego 5 02 004 Warsaw Poland

Department of Sexually Transmitted Diseases Diagnostics Medical University of Warsaw Koszykowa 82A 02 008 Warsaw Poland

Zobrazit více v PubMed

Antimicrob Agents Chemother. 2015 Jan;59(1):717-20 PubMed

Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80 PubMed

Antimicrob Agents Chemother. 2013 Nov;57(11):5225-32 PubMed

Antimicrob Agents Chemother. 2014 Aug;58(8):4984-5 PubMed

J Antimicrob Chemother. 2012 Aug;67(8):1858-60 PubMed

Euro Surveill. 2013 Jan 17;18(3):null PubMed

Med Dosw Mikrobiol. 2011;63(2):115-20 PubMed

Emerg Infect Dis. 2011 Jan;17 (1):148-9 PubMed

Antimicrob Agents Chemother. 2010 Mar;54(3):969-76 PubMed

Indian J Med Microbiol. 2015 Jan-Mar;33(1):39-42 PubMed

J Antimicrob Chemother. 2014 Jun;69(6):1517-25 PubMed

Mol Microbiol. 2005 Sep;57(5):1238-51 PubMed

Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45 PubMed

Acta Microbiol Immunol Hung. 2012 Jun;59(2):157-69 PubMed

BMC Infect Dis. 2014 Feb 25;14:106 PubMed

J Antimicrob Chemother. 2013 Jul;68(7):1567-71 PubMed

N Engl J Med. 2014 Nov 6;371(19):1850-1 PubMed

BMC Infect Dis. 2014 Feb 06;14:65 PubMed

J Clin Microbiol. 2015 Jan;53(1):191-200 PubMed

BMC Infect Dis. 2014 Aug 22;14:454 PubMed

Sex Transm Dis. 2011 Apr;38(4):329-33 PubMed

J Antimicrob Chemother. 2010 Aug;65(8):1615-8 PubMed

J Antimicrob Chemother. 2000 Jun;45(6):777-82 PubMed

Sex Transm Infect. 2013 Dec;89 Suppl 4:iv28-35 PubMed

BMC Infect Dis. 2014 Nov 27;14:622 PubMed